DK2877173T3 - Antagonister / inverse agonister til cannabinoidreceptorer - Google Patents
Antagonister / inverse agonister til cannabinoidreceptorer Download PDFInfo
- Publication number
- DK2877173T3 DK2877173T3 DK13822747.5T DK13822747T DK2877173T3 DK 2877173 T3 DK2877173 T3 DK 2877173T3 DK 13822747 T DK13822747 T DK 13822747T DK 2877173 T3 DK2877173 T3 DK 2877173T3
- Authority
- DK
- Denmark
- Prior art keywords
- antagonists
- inverse agonists
- cannabinoid receptors
- cannabinoid
- receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675806P | 2012-07-25 | 2012-07-25 | |
| US201361787214P | 2013-03-15 | 2013-03-15 | |
| US13/950,195 US8680131B2 (en) | 2012-07-25 | 2013-07-24 | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
| PCT/US2013/051919 WO2014018695A1 (en) | 2012-07-25 | 2013-07-25 | Cannabinoid receptor antagonists/inverse agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2877173T3 true DK2877173T3 (da) | 2020-02-24 |
Family
ID=49995474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13822747.5T DK2877173T3 (da) | 2012-07-25 | 2013-07-25 | Antagonister / inverse agonister til cannabinoidreceptorer |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8680131B2 (da) |
| EP (1) | EP2877173B1 (da) |
| JP (1) | JP6249534B2 (da) |
| CN (2) | CN104640543A (da) |
| AU (1) | AU2013295741B2 (da) |
| CA (1) | CA2879741C (da) |
| DK (1) | DK2877173T3 (da) |
| ES (1) | ES2771323T3 (da) |
| HR (1) | HRP20200212T1 (da) |
| HU (1) | HUE048386T2 (da) |
| IL (1) | IL236789A (da) |
| IN (1) | IN2015DN01503A (da) |
| MX (1) | MX364912B (da) |
| PL (1) | PL2877173T3 (da) |
| PT (1) | PT2877173T (da) |
| WO (1) | WO2014018695A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680131B2 (en) | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
| US9837765B2 (en) * | 2015-06-25 | 2017-12-05 | Microsoft Technology Licensing, Llc | Apparatus for ejecting at least one integrated circuit card |
| US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
| US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255093A1 (en) | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| ATE346047T1 (de) | 2000-03-23 | 2006-12-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer aktivität |
| AR033046A1 (es) * | 2001-03-22 | 2003-12-03 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1, composicion farmaceutica y metodos de preparacion |
| PL368441A1 (en) | 2001-09-21 | 2005-03-21 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| EP1429762A1 (en) | 2001-09-21 | 2004-06-23 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| WO2007131219A2 (en) | 2006-05-05 | 2007-11-15 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| JP5946192B2 (ja) * | 2010-11-18 | 2016-07-05 | ジェンリン ディスカバリーＪｅｎｒｉｎ Ｄｉｓｃｏｖｅｒｙ | 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬／逆作動薬 |
| US8680131B2 (en) * | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
-
2013
- 2013-07-24 US US13/950,195 patent/US8680131B2/en active Active
- 2013-07-25 CN CN201380048766.0A patent/CN104640543A/zh active Pending
- 2013-07-25 HU HUE13822747A patent/HUE048386T2/hu unknown
- 2013-07-25 MX MX2015001014A patent/MX364912B/es active IP Right Grant
- 2013-07-25 IN IN1503DEN2015 patent/IN2015DN01503A/en unknown
- 2013-07-25 WO PCT/US2013/051919 patent/WO2014018695A1/en active Application Filing
- 2013-07-25 EP EP13822747.5A patent/EP2877173B1/en active Active
- 2013-07-25 DK DK13822747.5T patent/DK2877173T3/da active
- 2013-07-25 CA CA2879741A patent/CA2879741C/en active Active
- 2013-07-25 ES ES13822747T patent/ES2771323T3/es active Active
- 2013-07-25 PT PT138227475T patent/PT2877173T/pt unknown
- 2013-07-25 AU AU2013295741A patent/AU2013295741B2/en not_active Ceased
- 2013-07-25 JP JP2015524433A patent/JP6249534B2/ja not_active Expired - Fee Related
- 2013-07-25 PL PL13822747T patent/PL2877173T3/pl unknown
- 2013-07-25 CN CN201910663070.8A patent/CN110372593A/zh active Pending
-
2014
- 2014-02-27 US US14/191,922 patent/US9133127B2/en not_active Expired - Fee Related
-
2015
- 2015-01-19 IL IL236789A patent/IL236789A/en active IP Right Grant
- 2015-09-03 US US14/844,297 patent/US9517228B2/en active Active
-
2016
- 2016-12-13 US US15/377,662 patent/US9987253B2/en active Active
-
2018
- 2018-05-29 US US15/991,705 patent/US10617673B2/en not_active Expired - Fee Related
-
2020
- 2020-02-10 HR HRP20200212TT patent/HRP20200212T1/hr unknown
- 2020-03-04 US US16/809,380 patent/US11179370B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9987253B2 (en) | 2018-06-05 |
| AU2013295741A1 (en) | 2015-03-12 |
| US20180353478A1 (en) | 2018-12-13 |
| IN2015DN01503A (da) | 2015-07-03 |
| US9517228B2 (en) | 2016-12-13 |
| US20140031404A1 (en) | 2014-01-30 |
| CN104640543A (zh) | 2015-05-20 |
| US20140329875A1 (en) | 2014-11-06 |
| MX2015001014A (es) | 2015-08-14 |
| US8680131B2 (en) | 2014-03-25 |
| CA2879741A1 (en) | 2014-01-30 |
| US10617673B2 (en) | 2020-04-14 |
| JP2015523396A (ja) | 2015-08-13 |
| HRP20200212T1 (hr) | 2020-10-16 |
| HUE048386T2 (hu) | 2020-07-28 |
| US20170182004A1 (en) | 2017-06-29 |
| US20210023054A1 (en) | 2021-01-28 |
| EP2877173A1 (en) | 2015-06-03 |
| US20160058736A1 (en) | 2016-03-03 |
| EP2877173B1 (en) | 2019-11-13 |
| ES2771323T3 (es) | 2020-07-06 |
| MX364912B (es) | 2019-05-13 |
| CA2879741C (en) | 2020-09-29 |
| PL2877173T3 (pl) | 2020-08-10 |
| JP6249534B2 (ja) | 2017-12-20 |
| IL236789A (en) | 2017-07-31 |
| US11179370B2 (en) | 2021-11-23 |
| EP2877173A4 (en) | 2016-03-16 |
| CN110372593A (zh) | 2019-10-25 |
| PT2877173T (pt) | 2020-02-21 |
| US9133127B2 (en) | 2015-09-15 |
| WO2014018695A1 (en) | 2014-01-30 |
| AU2013295741B2 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3024468T3 (da) | T-cellereceptorer | |
| DK3071697T3 (da) | Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er) | |
| DK3848027T3 (da) | Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer | |
| BR112014027348A2 (pt) | compostos agonistas duplos gip-glp-1 e métodos | |
| DK3030581T3 (da) | Antistofbindingssteder, der er specifikke for egfrviii | |
| DK2928870T3 (da) | Neurotensin-receptorligander | |
| FR22C1005I1 (fr) | Nouveaux agonistes des recepteurs adrenergiques alpha2 | |
| DK3312169T3 (da) | 5-ht3 receptorantagonister | |
| DK2821407T3 (da) | Piperidinoncarboxamidazaindan-cgrp receptorantagonister | |
| DK3385252T3 (da) | Cannabinoidreceptormodulatorer | |
| DK3456743T3 (da) | Oncostatin m-receptorantigenbindingsproteiner | |
| SMT201600441B (it) | Nuovi agenti antimalarici | |
| FI10595U1 (fi) | Testausadapteri | |
| IL240019A0 (en) | Estrogen receptor inhibitors | |
| HK1202546A1 (en) | Novel adamantyl derivatives as cannabinoid receptor agonists | |
| DK2877173T3 (da) | Antagonister / inverse agonister til cannabinoidreceptorer | |
| DK2861209T3 (da) | Somatostatinreceptoragonistformuleringer | |
| BR112015005750A2 (pt) | antagonistas peptídicos do receptor de vasopressina-2 | |
| BR302013000981S1 (pt) | Configuração aplicada em suporte para dispositivo de avaliação | |
| IL243730A0 (en) | Vasopressin-2 receptor agonists | |
| DK3074384T3 (da) | Amidderivater til gpr119-agonist | |
| DK2964206T3 (da) | Beta-2-adrenerg receptoragonist til forbedring af farvetilpasning af hudar | |
| GB201312010D0 (en) | Receptor Agonists | |
| FR3003539B1 (fr) | Structure anti-erosion pour aeronefs | |
| FR2993749B1 (fr) | Herisson pour epandeur |